ASTELLAS PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,506 JPY | +3.51% |
|
+1.72% | -10.68% |
| 25/04 | Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024 | |
| 25/04 | Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 31,86,231 | 31,05,395 | 31,61,421 | 35,19,738 | 33,81,409 | 27,00,238 | - | - |
| Enterprise Value (EV) 1 | 28,75,157 | 27,77,545 | 28,29,733 | 32,03,752 | 30,04,569 | 29,46,773 | 32,12,253 | 31,21,296 |
| P/E ratio | 14.4 x | 16 x | 26.2 x | 28.5 x | 34.7 x | 173 x | 25.7 x | 15.6 x |
| Yield | 2.29% | 2.39% | 2.47% | 2.62% | 3.19% | 4.69% | 4.93% | 5.27% |
| Capitalization / Revenue | 2.44 x | 2.39 x | 2.53 x | 2.72 x | 2.23 x | 1.84 x | 1.62 x | 1.54 x |
| EV / Revenue | 2.2 x | 2.14 x | 2.26 x | 2.47 x | 1.98 x | 1.84 x | 1.93 x | 1.78 x |
| EV / EBITDA | 9.35 x | 8.95 x | 13.6 x | 13.6 x | 12.6 x | 16.1 x | 11 x | 7.76 x |
| EV / FCF | 12.3 x | -16.6 x | 10.3 x | 14.1 x | 10.3 x | -5.46 x | 14.9 x | 11.3 x |
| FCF Yield | 8.12% | -6.04% | 9.73% | 7.08% | 9.7% | -18.3% | 6.69% | 8.83% |
| Price to Book | 2.49 x | 2.41 x | 2.28 x | 2.39 x | 2.24 x | 1.85 x | 1.83 x | 1.76 x |
| Nbr of stocks (in thousands) | 19,21,152 | 18,58,405 | 18,57,474 | 18,41,831 | 17,95,756 | 17,92,986 | - | - |
| Reference price 2 | 1,658 | 1,671 | 1,702 | 1,911 | 1,883 | 1,506 | 1,506 | 1,506 |
| Announcement Date | 25/04/19 | 14/05/20 | 27/04/21 | 27/04/22 | 27/04/23 | 25/04/24 | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Maart | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13,06,348 | 13,00,843 | 12,49,528 | 12,96,163 | 15,18,619 | 16,03,672 | 16,64,834 | 17,58,430 |
| EBITDA 1 | 3,07,370 | 3,10,387 | 2,08,703 | 2,35,370 | 2,38,767 | 1,83,358 | 2,90,770 | 4,02,117 |
| EBIT 1 | 2,43,912 | 2,43,991 | 1,36,051 | 1,55,686 | 1,33,029 | 25,518 | 1,43,256 | 2,31,489 |
| Operating Margin | 18.67% | 18.76% | 10.89% | 12.01% | 8.76% | 1.59% | 8.6% | 13.16% |
| Earnings before Tax (EBT) 1 | 2,48,967 | 2,45,350 | 1,45,324 | 1,56,886 | 1,32,361 | 24,969 | 1,36,946 | 2,26,419 |
| Net income 1 | 2,22,265 | 1,95,411 | 1,20,589 | 1,24,086 | 98,714 | 17,045 | 1,05,591 | 1,73,587 |
| Net margin | 17.01% | 15.02% | 9.65% | 9.57% | 6.5% | 1.06% | 6.34% | 9.87% |
| EPS 2 | 115.0 | 104.2 | 64.93 | 67.08 | 54.24 | 9.510 | 58.63 | 96.59 |
| Free Cash Flow 1 | 2,33,440 | -1,67,795 | 2,75,459 | 2,26,705 | 2,91,326 | -5,86,348 | 2,14,887 | 2,75,506 |
| FCF margin | 17.87% | -12.9% | 22.05% | 17.49% | 19.18% | -37.3% | 12.91% | 15.67% |
| FCF Conversion (EBITDA) | 75.95% | - | 131.99% | 96.32% | 122.01% | - | 73.9% | 68.51% |
| FCF Conversion (Net income) | 105.03% | - | 228.43% | 182.7% | 295.12% | - | 203.51% | 158.71% |
| Dividend per Share 2 | 38.00 | 40.00 | 42.00 | 50.00 | 60.00 | 70.62 | 74.27 | 79.36 |
| Announcement Date | 25/04/19 | 14/05/20 | 27/04/21 | 27/04/22 | 27/04/23 | 25/04/24 | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 Q3 | 2025 Q4 | 2025 S2 | 2026 S1 | 2026 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6,50,470 | - | 6,15,480 | - | 3,25,523 | 6,51,666 | 3,40,627 | 3,03,870 | - | 3,81,791 | 3,80,394 | 7,62,185 | 4,02,180 | 3,54,254 | 3,74,990 | 3,92,148 | 7,67,138 | 4,21,932 | 4,14,602 | - | 4,08,629 | 4,28,866 | 8,00,647 | 4,57,556 | 4,02,032 | - | - | - |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 70,087 | 42 | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 1,62,196 | - | 86,872 | - | 54,079 | 90,169 | 79,202 | -13,685 | - | 33,147 | 86,744 | 1,19,891 | 61,388 | -48,250 | 45,794 | 5,222 | 51,016 | 23,103 | -48,601 | - | 25,793 | 35,163 | 83,888 | 49,695 | -42,296 | - | - | - |
| Operating Margin | 24.94% | - | 14.11% | - | 16.61% | 13.84% | 23.25% | -4.5% | - | 8.68% | 22.8% | 15.73% | 15.26% | -13.62% | 12.21% | 1.33% | 6.65% | 5.48% | -11.72% | - | 6.31% | 8.2% | 10.48% | 10.86% | -10.52% | - | - | - |
| Earnings before Tax (EBT) 1 | 1,61,584 | - | 89,091 | - | 53,255 | 89,085 | 78,317 | -10,516 | - | 31,679 | 88,801 | 1,20,480 | 59,758 | -47,877 | 46,850 | 5,328 | 52,178 | 21,452 | -48,661 | - | 23,490 | 33,394 | 80,888 | 45,792 | -41,144 | - | - | - |
| Net income 1 | 1,28,527 | - | 72,838 | - | 40,922 | 71,609 | 60,886 | -8,409 | - | 24,812 | 71,622 | 96,434 | 48,405 | -46,125 | 33,129 | -1,459 | 31,670 | 18,653 | -33,278 | - | 17,632 | 25,467 | 59,857 | 34,924 | -31,769 | - | - | - |
| Net margin | 19.76% | - | 11.83% | - | 12.57% | 10.99% | 17.87% | -2.77% | - | 6.5% | 18.83% | 12.65% | 12.04% | -13.02% | 8.83% | -0.37% | 4.13% | 4.42% | -8.03% | - | 4.31% | 5.94% | 7.48% | 7.63% | -7.9% | - | - | - |
| EPS 2 | 68.16 | - | 39.21 | - | 22.09 | 38.65 | 32.86 | -4.430 | - | 13.59 | 39.28 | 52.87 | 26.56 | -25.19 | 18.46 | -0.8000 | 17.66 | 10.40 | -18.55 | - | 9.885 | 14.12 | 33.40 | 20.20 | -19.31 | - | - | - |
| Dividend per Share 2 | 20.00 | 20.00 | 21.00 | 21.00 | - | 25.00 | - | - | 25.00 | - | - | 30.00 | - | - | - | 35.00 | 35.00 | - | 35.00 | 35.00 | - | - | 37.00 | - | - | 37.00 | 39.00 | 39.00 |
| Announcement Date | 31/10/19 | 14/05/20 | 30/10/20 | 27/04/21 | 29/10/21 | 29/10/21 | 02/02/22 | 27/04/22 | 27/04/22 | 01/08/22 | 31/10/22 | 31/10/22 | 06/02/23 | 27/04/23 | 01/08/23 | 01/11/23 | 01/11/23 | 05/02/24 | 25/04/24 | - | - | - | - | - | - | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 5,03,449 | 5,12,015 | 4,21,059 |
| Net Cash position 1 | 3,11,074 | 3,27,850 | 3,31,688 | 3,15,986 | 3,76,840 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | 1.9 x | 1.761 x | 1.047 x |
| Free Cash Flow 1 | 2,33,440 | -1,67,795 | 2,75,459 | 2,26,705 | 2,91,326 | -5,86,348 | 2,14,887 | 2,75,506 |
| ROE (net income / shareholders' equity) | 17.6% | 15.3% | 9% | 8.7% | 6.7% | 1.1% | 7.42% | 11.5% |
| ROA (Net income/ Total Assets) | 13.3% | 11.6% | 6.33% | 6.81% | 5.53% | 4.43% | 4.48% | 7.23% |
| Assets 1 | 16,76,516 | 16,78,858 | 19,05,121 | 18,21,523 | 17,85,770 | 3,02,888 | 23,55,092 | 23,99,595 |
| Book Value Per Share 2 | 667.0 | 694.0 | 748.0 | 799.0 | 839.0 | 890.0 | 821.0 | 858.0 |
| Cash Flow per Share 2 | 148.0 | 140.0 | 104.0 | 110.0 | 112.0 | 97.50 | 179.0 | 195.0 |
| Capex 1 | 25,190 | 41,267 | 31,384 | 30,739 | 36,441 | 50,975 | 61,860 | 58,060 |
| Capex / Sales | 1.93% | 3.17% | 2.51% | 2.37% | 2.4% | 3.24% | 3.72% | 3.3% |
| Announcement Date | 25/04/19 | 14/05/20 | 27/04/21 | 27/04/22 | 27/04/23 | 25/04/24 | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,506
JPY
Average target price
2,025
JPY
Spread / Average Target
+34.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.68% | 17.15B | |
| +25.83% | 661B | |
| +27.20% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.70% | 231B | |
| +5.07% | 200B | |
| -9.12% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4503 Stock
- Financials Astellas Pharma Inc.
